Detail View

CD4+ cytotoxic T cells: an emerging effector arm of anti-tumor immunity
Citations

WEB OF SCIENCE

Citations

SCOPUS

Metadata Downloads

DC Field Value Language
dc.contributor.author Jeong, Seongmin -
dc.contributor.author Jang, Nawon -
dc.contributor.author Kim, Minchae -
dc.contributor.author Choi, Il-Kyu -
dc.date.accessioned 2023-07-12T11:40:20Z -
dc.date.available 2023-07-12T11:40:20Z -
dc.date.created 2023-04-04 -
dc.date.issued 2023-02 -
dc.identifier.issn 1976-6696 -
dc.identifier.uri http://hdl.handle.net/20.500.11750/46130 -
dc.description.abstract While CD8+ cytotoxic T cells have long been considered the primary effector in controlling tumors, the involvement of CD4+ “helper” T cells in anti-tumor immunity has been underappreciated. The investigations of intra-tumoral T cells, fueled by the recent advances in genomic technologies, have led to a rethinking of the indirect role of CD4+ T cells that have traditionally been described as a “helper”. Accumulating evidence from preclinical and clinical studies indicates that CD4+ T cells can acquire intrinsic cytotoxic properties and directly kill various types of tumor cells in a major histocompatibility complex class II (MHC-II)-dependent manner, as opposed to the indirect “helper” function, thus underscoring a potentially critical contribution of CD4+ cytotoxic T cells to immune responses against a wide range of tumor types. Here, we discuss the biological properties of anti-tumor CD4+ T cells with cytotoxic capability and highlight the emerging observations suggesting their more significant role in anti-tumor immunity than previously appreciated. © 2023 by the The Korean Society for Biochemistry and Molecular Biology -
dc.language English -
dc.publisher 생화학분자생물학회 -
dc.title CD4+ cytotoxic T cells: an emerging effector arm of anti-tumor immunity -
dc.type Article -
dc.identifier.doi 10.5483/BMBRep.2023-0014 -
dc.identifier.scopusid 2-s2.0-85151044432 -
dc.identifier.bibliographicCitation Jeong, Seongmin. (2023-02). CD4+ cytotoxic T cells: an emerging effector arm of anti-tumor immunity. BMB Reports, 56(3), 140–144. doi: 10.5483/BMBRep.2023-0014 -
dc.identifier.kciid ART002943797 -
dc.description.isOpenAccess FALSE -
dc.subject.keywordAuthor Anti-tumor immunity -
dc.subject.keywordAuthor Cancer immunotherapy -
dc.subject.keywordAuthor CD4+ cytotoxic T cells -
dc.subject.keywordAuthor CD4+ “helper” T cells -
dc.subject.keywordAuthor MHC-II antigen presentation -
dc.subject.keywordPlus HLA CLASS-II -
dc.subject.keywordPlus EXPRESSION -
dc.subject.keywordPlus CANCER -
dc.subject.keywordPlus ACTIVATION -
dc.subject.keywordPlus LANDSCAPE -
dc.subject.keywordPlus MELANOMA -
dc.subject.keywordPlus BLOCKADE -
dc.citation.endPage 144 -
dc.citation.number 3 -
dc.citation.startPage 140 -
dc.citation.title BMB Reports -
dc.citation.volume 56 -
Show Simple Item Record

File Downloads

  • There are no files associated with this item.

공유

qrcode
공유하기

Related Researcher

최일규
Choi, Il-Kyu최일규

Department of New Biology

read more

Total Views & Downloads